BI adds to cancer pipeline with CureVac’s mRNA vaccine CV9202; Terminated
CureVac GMBH (oncology and infectious disease mRNA therapeutics) licensed Boehringer Ingelheim GMBH exclusive worldwide rights to its Phase I mRNA vaccine CV9202 for lung cancer.
- Antisense, Oligonucleotides
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.